GLP-1受体激动剂对高糖损伤足细胞保护机制的研究进展

Research progress in protective mechanism of GLP-1 receptor agonists on podocytes injured by hyperglycemia

糖尿病肾脏病(DKD)是造成糖尿病患者终末期肾脏病和死亡的主要原因之一,足细胞损伤与DKD的发生、发展密切相关,高糖状态会导致足细胞数量和密度的下降。近年来,胰高血糖素样肽(GLP)-1受体激动剂逐渐展示出潜在的肾脏保护作用,较多研究发现除降糖作用以外,GLP-1受体激动剂还可通过抗氧化应激、抗炎、抑制自噬和凋亡、改善胰岛素抵抗等多种途径改善足细胞损伤,作用机制涉及多条信号通路。探讨GLP-1受体激动剂对足细胞的保护作用及其机制,可为其用于DKD的防治提供理论依据。

Diabetic kidney disease( DKD) is one of the main causes of end-stage renal disease and death in diabetic patients. Podocyte injury is closely related to the occurrence and development of DKD, and high glucose state can lead to a decrease in the number and density of podocytes. In recent years, glucagon-like peptide( GLP)-1 receptor agonists have gradually shown potential renal protection. Many studies have found that in addition to their hypoglycemic effect, GLP-1 receptor agonists can also improve podocyte injury by anti-oxidative stress, anti-inflammatory, inhibiting autophagy and apoptosis, and improving insulin resistance. The mechanism of action involves multiple signaling pathways. Exploring the protective effect and mechanism of GLP-1 receptor agonists on podocytes can provide a theoretical basis for their use in the prevention and treatment of DKD.